Company Frazier Lifesciences Acquisition Corporation
Equities
NAMS
NL00150012L7
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
20.3 EUR | -8.56% | +1.79% | +98.75% |
Business Summary
Number of employees: 29
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Transformative Therapies for Cardio-metabolic Diseases
100.0
%
| 102 | 100.0 % | 15 | 100.0 % | -85.13% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Italy
100.0
%
| 102 | 100.0 % | 15 | 100.0 % | -85.13% |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 89,266,673 | 84,112,133 ( 94.23 %) | 0 | 94.23 % |
Company contact information
NewAmsterdam Pharma Co. NV
Gooimeer 2-35
1411 DC, Naarden
+31 35 206 2971
http://www.newamsterdampharma.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+98.75% | 2B | |
+3.72% | 106B | |
+7.02% | 23.47B | |
-14.82% | 21.9B | |
-7.05% | 18.77B | |
-38.55% | 17.85B | |
-9.77% | 16.78B | |
+4.99% | 14.41B | |
+35.62% | 12.86B | |
+323.80% | 8.78B |
- Stock Market
- Equities
- NAMS Stock
- Company Frazier Lifesciences Acquisition Corporation